ArticleScientific reports2025
Acipimox as a potential antioxidant and neuromodulator mitigates high fat diet induced cognitive dysfunction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A derivative of niacin i.e. Acipimox (Acx), exhibits antioxidant properties among in vitro and in vivo studies; however, its potential application for managing neurological deficits remains largely unexplored. This study explores the impacts of Acx on various physiological and neurological factors, including food consumption, body weight control, cognitive functions, oxidative stress neuroinflammation responses, expression of serotonin (5-HT) metabolism, and 5HT1A receptor within the midbrain and cerebral cortex. A total of 48 male albino rats (n = 8 per group) was randomly assigned to six experimental groups: (1) Vehicle (Vh) + Normal diet (NoD) (2) NoD + Acx (25 mg/kg (low dose) (3) NoD + Acx (50 mg/kg) (high dose), (4) Vh + High fat-rich diet (Hifrd), (5) Hifrd + Acx (25 mg/kg)(6) Hifrd + Acx (50 mg/kg). Rats were administered their respective treatment for 8 weeks (56 days). A behavioral evaluation such as Morris Water Maze (MWM) to assess spatial memory performance and the Y-maze test to measure spontaneous behavioral changes. Following decapitation, brain tissue from the midbrain and cerebral cortex was carefully dissected for further analysis. The findings revealed that Hifrd led to memory deficits, increased body weight, and heightened food consumption, effects that were mitigated via repeated administration of both doses of Acx. Additionally, Hifrd triggered oxidative stress-related neuroinflammation, altered 5-HT metabolism, and affected receptor expression of 5HT1A in both the midbrain and cerebral cortex following changes that were significantly modulated by Acx. Owing to its antioxidant, anti-inflammatory, and neuromodulatory effects, Acx mitigates Hifrd-induced memory impairments. Based on these findings, it suggests that Acx may have the potential to improve cognitive function and modulate neurological parameters in Hifrd-fed rats; however, further studies are required to determine its therapeutic relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.